Drug Profile
Monoclonal antibody 93KA9
Alternative Names: Human anti-VZV antibodyLatest Information Update: 09 Aug 2002
Price :
$50
*
At a glance
- Originator Novartis
- Developer PDL BioPharma
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Varicella zoster virus infections
Most Recent Events
- 20 Feb 1997 New profile
- 20 Feb 1997 Preclinical development for Varicella zoster virus infections in USA (Unknown route)